Study of a new drug for KRAS G12D colorectal or pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental drug (GDC-7035) given with other cancer treatments to see if it is safe and works in people with advanced colorectal or pancreatic cancer that has a specific genetic change called KRAS G12D.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer or pancreatic cancer that has spread or cannot be removed by surgery.
- Your tumor has a specific genetic marker called KRAS G12D (confirmed by a lab test).
- You do not have untreated or active brain metastases.
- You do not have significant liver disease or a history of serious heart problems.
- You can take medications by mouth and your digestive system absorbs food normally.
- If you can become pregnant or father a child, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.